Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Raymond, Eric; Dahan, Laetitia; Raoul, Jean-Luc; Bang, Yung-Jue; Borbath, Ivan; Lombard-Bohas, Catherine; Valle, Juan; Metrakos, Peter; Smith, Denis; Vinik, Aaron; Chen, Jen-Shi; Hörsch, Dieter; Hammel, Pascal; Wiedenmann, Bertram; Van Cutsem, Eric; Patyna, Shem; Ray Lu, Dongrui; Blanckmeister, Carolyn; Chao, Richard; Ruszniewski, Philippe

doi:10.1056/NEJMoa1003825

Public

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Shared by NobleBlocks on Feb 10, 2011 • 12:00 AM UTC

Authors:

Eric Raymond

Laetitia Dahan

Jean-Luc Raoul

Abstract

BACKGROUND: The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. METHODS: We conducted a multinational, randomized, double-blind, placebo-controlled phase 3 trial of sunitinib in patients wit...

Discussions